Chai Discovery Raises $130M Series B to Accelerate AI-Driven Drug Discovery Platform
核心洞察
Chai Discovery (搜索) secured $130 million in Series B funding co-led by Oak HC/FT (搜索) and General Catalyst (搜索), achieving a $1.3 billion valuation and bringing total funding to over $225 million.
The company's Chai-2 (搜索) platform represents a breakthrough in AI drug design, achieving double-digit experimental success rates in de novo antibody design with 100-fold improvement over previous computational methods.
The funding will accelerate development of a "computer-aided design suite" for molecules, targeting hard-to-drug targets and aiming to compress the traditional decade-long drug development timeline.
Chai Discovery (搜索), an artificial intelligence company focused on molecular discovery, announced a $130 million Series B financing round that values the company at $1.3 billion. The round was co-led by Oak HC/FT (搜索) and General Catalyst (搜索), with participation from notable investors including OpenAI (搜索), Thrive Capital (搜索), Dimension, Menlo Ventures (搜索), and other prominent venture firms.
The funding comes just months after Chai Discovery (搜索)'s $70 million Series A round and follows the company's recent breakthrough in designing molecules with important "developability" properties for historically challenging "hard-to-drug" targets.
Revolutionary AI Platform Shows Unprecedented Success Rates
Chai Discovery (搜索)'s latest achievement centers on Chai-2 (搜索), described as the first zero-shot generative platform that achieves double-digit experimental success rates in de novo antibody design. This represents a 100-fold improvement over previous computational methods, marking a significant leap forward in AI-driven drug discovery capabilities.
"We're standing on the precipice of a new era for the biopharmaceutical industry," said Josh Meier, co-founder and CEO of Chai Discovery (搜索). "We're in awe of the rate of progress on the models – what looked like five-year problems just months ago are now getting solved in weeks. Our latest models can design molecules that have properties we'd want from actual drugs, and tackle challenging targets that have been out of reach."
The company's platform predicts and reprograms interactions between biochemical molecules, converting what has traditionally been a lengthy iteration cycle into a computational process. This approach aims to materially compress the time to first-in-human studies and accelerate overall commercialization timelines.
Addressing Industry Pain Points
The pharmaceutical industry faces significant challenges in drug development, with traditional processes taking over a decade and costing upwards of a billion dollars to bring a medicine from bench to bedside. Annie Lamont, Co-Founder & Managing Partner at Oak HC/FT (搜索), emphasized the critical need for transformation in this space.
"Nowhere is AI transformation more needed than in drug development – the process is slow, expensive, and imprecise," Lamont stated. "The Chai Discovery (搜索) team is rewriting that story, fusing world-class AI and biological expertise to dramatically accelerate how medicines are discovered."
According to President Jack Dent, 2026 is positioned to be "the year of AI deployment in pharmaceuticals," suggesting the industry is approaching a critical inflection point in adopting AI-driven approaches.
Strategic Vision and Market Impact
Elena Viboch, Managing Director at General Catalyst (搜索), highlighted the transformative potential of Chai's approach: "We believe biology is becoming programmable, rewiring what was once an empirical art into an engineered discipline. Chai's team is leading this transformation – advancing the technical frontier and expanding what's possible in therapeutics."
The company plans to use the Series B funding to accelerate research and product development while expanding commercialization efforts. The ultimate goal is building a comprehensive "computer-aided design suite" for molecules that can tackle previously undruggable targets and enable the development of first-in-class and best-in-class therapeutics.
CEO Meier reflected on the industry's evolution, noting: "Looking back over the last five to 10 years, there's been so much hype on AI for drug discovery. This is the year things started working."
The Series B round brings Chai Discovery (搜索)'s total funding to more than $225 million, with Annie Lamont from Oak HC/FT (搜索) and Hemant Taneja from General Catalyst (搜索) joining the company's board of directors. New investors Emerson Collective and Glade Brook also participated in the round alongside existing backers.